Summary. -Despite the success of highly active antiretroviral therapy, AIDS still remains as one of the most important world health problems. Toxicity of current available drugs and inevitable emergence of multi-drug resistant strains makes things worse. In the present study a series of novel Biginelli-type pyrimidine compounds were evaluated as potential anti-human immunodefi ciency virus (HIV)-1 agents using green fl uorescence protein (GFP) reporter single round HIV-1 infection assay. Th e rate of infected cells was monitored by fl owcytometry. Th e eff ect of compounds on the cellular proliferation was considered as the cyotoxicity. Th e anti-HIV-1 active compounds were selected for HIV-1 replication and syncytium formation assays. Th e antiretroviral activity of compounds was measured against luciferase reporter A murine leukemia virus (AMLV) virions as the retrovirus control. Compounds 2, 5, 6, 8, 11, 12, 13, 17, 18, 20, and 21 were the most potent against HIV-1. Compound 8 had the 50% inhibitory concentration (IC 50 ) of 100 nmol/l for inhibiting HIV-1 replication and 50% cytotoxic concentration (CC 50 ) was up to 100 μmol/l (therapeutic index (TI) >1000). Results show that the active compounds were able to inhibit the retrovirus control as well. Analysis of structure of the studied compounds proved relationships with their anti-HIV-1 eff ects. Some of the studied compounds seem to be promising anti-HIV-1 drug candidates. Structural manipulation based on the well-defi ned structure-activity relationships might propose some new leads for anti-HIV-1 drug discovery programs.
Introduction
Depletion of CD4 T lymphocytes is the main feature of AIDS, the infection caused by HIV-1 (Barre- Sinoussi et al., 1983; Fauci et al., 1984) . Th is virus enters the host immune system cells through the interaction of ENVs with the target cell surface receptors: CD4 and one of the two chemokine receptors, CCR5 or CXCR4 (Alkhatib et al., 1996; Choe et al., 1996; Dragic et al., 1996) . HIV-1 is an RNA virus, belonging to the retrovirus family. Aft er target cell entry, virion transcribes its RNA genome to DNA and then integrates the proviral DNA to the host cell genome using reverse transcriptase (RT) and indegrase (IN) enzymes, respectively (Cook, 1993) . Virus-producing cells have much shorter halflives than latently infected ones in HIV-1-infected humans, suggesting a role for viral infection in the destruction of host cells. HIV-1 infection in tissue-culture conditions leads to syncytium formation and single cell lysis which are called cytopathic eff ects (Dedera and Ratner, 1991) . Th ere are reports of the cytostatic or cytotoxic eff ects of HIV-1 proteins Tat, Vif, Vpr, Nef, and protease in cultured cells (Bartz and Emerman, 1999; Chen et al., 1999; Okada et al., 1997; Rasola et al., 2001) . However, lysis of cultured T cells infected by HIV-1 and depletion of these cells in simian immunodeficiency virus infected monkeys has been observed without these viral proteins (Cao et al., 1996; McCloskey et al., 1997) . Expression of the HIV-1 envelope glycoprotein (ENV) also results in cytopathic eff ects in cells expressing the appropriate receptors (LaBonte et al., 2003) . HIV-1 ENVs can trigger the formation of lethal syncytia among infected cells due to cell-cell fusion (Sodroski et al., 1986) .
Despite the success of highly active antiretroviral therapy, AIDS remains one of the most important world health problems. RT and IN which have critical roles during HIV-1 replication can be exploited as targets for anti-HIV-1 therapy and strongly show eff ectiveness particularly when employed in combination. Highly active antiretroviral therapy (HAART) dramatically decreases the number of AIDS cases, however, it is not able to eradicate HIV-1 infection from patients completely (Barreca et al., 2005; Imamichi, 2004; Wilkin et al., 2010) . On the other hand, maintaining patients' adherence to antiretroviral therapy is diffi cult because of the toxicity of current available anti-HIV-1 substances (Siliciano et al., 2003; Tan et al., 2010) . Th e inevitable emergence of drug-resistant mutants and multi-drug resistant strains makes things worse (Grant et al., 2002; Obiako et al., 2010) . Th erefore, there is increasing impetus for the discovery of new anti-HIV agents against current targeted or alternative sites in the viral life cycle.
In the beginning of 1890s the Italian chemist Pietro Biginelli reported a novel method for the one pot synthesis of 4-aryl-3,4-dihydropyrimidine-2(1H)-ones (DHPMs) which are known today as Biginelli-type pyrimidines (Biginelli, 1893) . Aft er nine decades of being ignored, the pharmacological properties of this interesting heterocyclic scaff old attracted worthwhile attention of medicinal chemists (Kappe, 2000) . Since the early 1980s, a broad range of biological eff ects, including calcium channel modulation (Rovnyak et al., 1992) , adrenoceptor blocking activity (Barrow et al., 2000) , antitumor (Klein et al., 2007) , antibacterial (Ashok et al., 2007) , antioxidant (Stefani et al., 2006) and anti-infl ammatory (Bahekar and Shinde, 2004) activities has been ascribed to this class of heterocycles. DHPMs also possess antiviral activity (Hurst and Hull, 1961) . Nitracin, a nitrofuryl-substituted Biginelli-type pyrimidine has displayed good activity against the viruses of the trachoma group (Hurst, 1962) . 3,4-Dihydropyrimidine-2(1H)-one moiety has been found in batzelladine A and B, natural marine alkaloids. Th ese compounds are the fi rst low molecular weight natural products reported as inhibitors of the binding of HIV gp-120 to CD4 cells (Patil et al., 1995) .
In this study we report the anti-HIV-1 activity of forty-six 4-aryl-3,4-dihydropyrimidine-2(1H)-one (thione) derivatives. Single-round infection, replication and syncytium formation assays were the methods utilized for the evaluation of the anti-HIV-1 activity of the compounds. To prove the safety of the compounds, cytotoxicity was also determined.
Materials and Methods
Compounds. General structure and structural details of the compounds used in this study are shown in Table 1 . Th e preparation of compounds 1-16 was reported by our group previously (Soleymani and Memarian, 2010) . 34, 36, 38, 39, 41, 44, 45, and 46 were prepared according to literature (Besoluk et al., 2008; Jiang and You, 2007; Kumar et al., 2006; Lu et al., 2002; Russowsky et al., 2004; Zhan et al., 2008) . Th e rest of the studied compounds were not reported yet. Th e compounds were dissolved in DMSO at diff erent concentrations of 10 mmol/l to 10 μmol/l. Th ese stocks were diluted 100 times in cell environment so that the fi nal concentrations of compounds were 100 μmol/l to 10 nmol/l. Nevirapine (50 μmol/l) extracted from commercial tablets and DMSO (1% v/v) were used as positive and negative controls. All tests were performed in triplicate.
Cells and viruses. HEK293T, MT-2 and Cf2Th cells were used in this study. Cells were cultured in DMEM (293T and Cf2Th ) and RPMI 1640 (MT-2) mediums (Chemicon, USA) supplemented with 15% heat inactivated FBS (Gibco, South America) plus appropriate concentrations of L-Glutamine (Gibco, South America) and penicillin-streptomycin (Bioidea, Iran). Transfections were done using polyfect reagent (Qiagen, USA) according to the instruction. GFP reporter and single-cycle replicable (SCR) HIV virions were produced as previously described . pCL-ECO, pBABE-LUC and pMD2G (Addgene, USA) were used to produce luciferase reporter AMLV. Virus containing supernatants were collected and pooled 24, 48, and 72 hrs post transfection. Virus supernatants were clarifi ed by fi ltering through 0.22 μm fi lters. Some virus stocks were concentrated by centrifuging at 50,000 × g for 2 hrs at 4°C. Stocks were analyzed for p24 content (HIV P24 ELISA, BIOMERIEUX) and infectious titer was determined before aliquoting and storing at -70°C (Cavrois et al., 2004) .
Single-round infection assay. HIV-1 GFP and AMLV luciferase reporter virions were used for performing single-round infection assay. MT-2 cells (4×10 4 ) were placed in each well of 96 well plates and infected by GFP reporter HIV-1. Aft er 5.5 hrs, 200 μl of fresh medium was added to each well and cells were cultured for additional 3 days. Subsequently, the content of each well was transferred to the fl owcytometry tubes containing 1 ml RPMI 1640. Th e fraction of GFP positive cells in each well was quantifi ed using the fl owcytometry (Partec, Germany) (Campbell et al., 2007) . Concentration of compound which was able to inhibit the HIV-1 infection by 50% was considered as IC 50 .
Cf2Th cells were infected with 10 4 RT unit (RTU) luciferase reporter AMLV virions in each well of 96 well plates and cultured for 72 hrs. Cells were lysed and 100 μl of substrate (Promega, USA) was added to each well. Th e luminesence activity of plates was de- Table 1 . Chemical structure of pyrimidine derivates used in this study for anti HIV-1 activity termined by using luminometer device (EG&G Berthold LB 96V Microplate Luminometer) (Madani et al., 2007) . Replication assay. SCR virions are replicable no more than one cycle . Vesicular stomatitis virus glycoprotein (VSVG)-SCR virions can infect 293 T cells and complete their replication cycle by assembling of inactive virions. HEK293T cells (6×10 4 ) were seeded in each well of 24 well plates containing 250 μl of complete medium and infected with 400 ng P24 VSVG-SCR virions. Cells and virions were incubated together overnight and cells were then washed two times with pre-warmed 5% FBS supplemented DMEM. Complete medium (400 μl) was added into each well and cell supernatants were analyzed for p24 load aft er 48 hrs (HIV P24 ELISA, BIOMERIEUX).
Syncytium formation assay. MT-2 cells are sensitive to HIV induced syncytial formation. MT-2 cells (2×10 4 ) were seeded in 96 well plates containing 80 μl of fresh media and 700 ng P24 VSVG-SCR virions. Complete fresh medium (200 μl) was added into each well aft er 16 hrs. Cells were incubated 48 hrs and the syncytiums were counted under a light microscope (Nikon TR300) in fi ve fi elds of each well (Madani et al., 2007) .
Cytotoxicity assay. Toxicities of the compounds against MT-2 and 293T cells were quantifi ed using XTT (Roche Molecular Biochemicals) cell proliferation assay (Lin et al., 2003) . Cells were cultured in 96 well plates (3.5×10 4 cells/well) containing fresh phenol-red free medium and incubated for 72 hrs in a CO 2 incubator. Subsequently, 50 μl of XTT (sodium 3-[1 (phenylaminocarbonyl)-3,4-tetrazolium]-bis(4-methoxy-6-nitro)benzene sulfonic acid) was added into each well and incubated 4 hrs at 37°C. Plates were evaluated by using Bio-Tek ELx 800 ELISA reader at the test and reference OD of 450 and 630 nm, respectively. Concentration which reduces proliferation of 50% of cells was considered as CC 50 .
Results

Anti-HIV-1 potential of the compounds
A primary screening of the studied compounds for anti-HIV-1 potential was performed using single-round infection and cytotoxicity assays. Th e anti-HIV-1 activity of the compounds was evaluated using single-round infection assay. Th e inhibitory and cytotoxicity of each compound is shown in Table 2 . Compounds 5, 6, 10, 11, and 12 had considerable anti-HIV-1 activity with no remarkable toxicity for the cells. Since they were not toxic up to their maximal solubility concentration, selectivity index (SI) could not be determined mathematically. Some other compounds had not only good anti-HIV-1 activity but also toxicity on MT-2 cells (compounds 2, 4, 8, 9, 20, 21, 27, and 40) . Compounds 19, 20, 21, 30 , and 41 were the most toxic among the tested compounds. Compound 20 and 40 were the most active ones for inhibiting HIV infection (IC 50 of 1.1 μmol/l) but, they were highly toxic as well. Compound 10 inhibited viral infection with IC 50 and IC 25 of 9 and 0.07 μmol/l, respectively but was not toxic. Th e calculated SI for this compound was >1428 which shows its considerable anti-HIV-1 potential. Compounds 22, 24, 26, 28, and 31 did not show any inhibitory eff ect and compounds 33, 34, 35, 36, 37, 38 , and 44 had neither of inhibitory and toxic eff ects up to the highest concentration.
Antiretroviral potential against AMLV and replication of HIV-1
Th e anti-HIV active compounds were evaluated for inhibition of HIV-1 replication and AMLV infection. Compounds 2, 5, 6, 8, 9, 10, 17, 18, 19, 20 , and 21 were the most potent compounds regarding the screening so their inhibitory activity was evaluated against HIV replication. Th e highly potent compounds showed similar anti-HIV activity in both, infection and replication assays (5, 6, 10, 11, and 12) . Th e calculated TI values for compounds 18, 19, 20 , and 21 were 333, 100, 97, and 101 respectively, which shows potent anti-HIV-1 activity. Compounds 6 and 10 did not show toxic eff ect for cells in their solubility range but compound 6 inhibited 50% of viral replication at concentration of 39 μmol/l. Compounds 20 and 21 had signifi cant anti HIV replication activity but they were highly toxic as well. Compound 8 had IC 50 of 100 μmol/l and concentration of CC 50 was 100 μmol/l. Th e TI value of compound 8 was more than 1000 which shows considerable anti-HIV-1 potential of this agent. Th e anti-AMLV activity of all compounds was similar to their anti-HIV activity (Table 3) . Compound 8 was not eff ective for inhibition of AMLV virions infection (IC 50 >100 μmol/l).
Inhibition of syncytium formation induced by HIV-1
In this study, syncytium formation, as a factor for HIV-1 replication and anti-HIV-1 activity of some active compounds was measured. Th e results of syncytium formation assay which shows the inhibitory eff ect of compounds for HIV-1 replication is shown in Table 3 . Compounds 19, 20, and 21 inhibit almost all the HIV-1 induced syncytium formation at concentration of 100 μmol/l. Compound 8 showed considerable anti-HIV-1 activity with lower toxicity among the studied compounds.
Discussion
A series of Biginelli-type pyrimidines were evaluated as potential anti-HIV-1 agents. A screening for anti-HIV-1 activity using single round HIV-1 infection assay as well as cytotoxicity evaluation of the studied compounds were performed. Compounds with high anti-HIV-1 potential were selected for anti-HIV-1 replication assay. Replication assay shows the ability of compounds for inhibiting replication cycle of HIV-1 virions from entry to release from the host cells. In order to determine if the compounds had specifi c activity against HIV-1, the antiviral activity of the compounds against AMLV as a retrovirus control was measured. Syncytium formation assay was considered for detecting the possible activity of some active compounds against HIV-1 induced cytopathic eff ects. Almost all compounds with the highest activity in infection assay showed similar results in inhibiting HIV replication (2, 6, 9, 17, 18, 20, and 21) . Compound 8 showed very high anti-HIV-1 activity in replication and syncytium formation assay, but on the other hand, it showed moderate eff ect in infection assay. Th is means, that it may inhibit the viral replication aft er insertion of provirus. All of the compounds which were evaluated for anti-AMLV activity showed similar results to anti-HIV-1 potential, leading us to conclusion, that this class of compounds is not aff ecting viral components.
Analysis of structure of studied compounds shows that all most active compounds (5, 6, 9, 10, 11, and 12) have a substituted phenyl group at C-4 position of the pyrimidine ring. Compounds with thienyl or substituted imidazole ring at this position do not show a remarkable anti-HIV-1effect (compare for example, the SI values of compounds 9-12 with the SI values of compounds 25 and 31). Compounds 11 and 12 with a nitrophenyl group at C-4 are the most active ones, but their selectivity indices were not possible to calculate mathematically since they were almost nontoxic to the MT-2 cells. All active compounds also have an aryl amide group at C-5 position of the pyrimidine ring. By comparing the SI value of compound 9 (912) with those for compounds 39 and 40 (4 and 18, respectively) we came to conclusion that the presence of an ester group at this position makes the compound less active. The last noteworthy point in the structure-activity relationships of the studied compounds can be concluded by comparing the selectivity indices of compounds 5 with 1, 39 with 41, and 40 with 42. As it can be seen, 2-thio carbonyl substitution at the C-2 position of the pyrimidine ring instead of 2-carbonyl group decreases the selectivity of the compound against the virion.
It should be emphasized that some of the most active compounds (5, 6, 8, 11, 12, and 13) were not so toxic to the target cell to disturb its normal activities and cause its death. Of course, the best scenario is that the drug doesn΄t aff ect the target cell at all. On the other hand, mentioned compounds showed high activity against HIV-1 infection and replication. Th ese compounds seem to be promising candidates. Structural manipulation based on the well-defi ned structure-activity relationships might propose some new leads for anti-HIV-1 drug discovery programs.
